|Bid||2,908.00 x 0|
|Ask||2,908.00 x 0|
|Day's Range||2,890.00 - 2,934.00|
|52 Week Range||2,336.50 - 3,659.00|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||10.86|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||2.03 (6.85%)|
|1y Target Est||3,825.26|
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
LONDON, Sept. 17, 2019 /PRNewswire/ -- British American Tobacco (BAT), is pleased to announce today that it has been listed in the Dow Jones Sustainability Indices (DJSI) for the 18th consecutive year – and has once again been named as industry leader in its most prestigious World Index. Created jointly by S&P Dow Jones Indices and RobecoSAM, the DJSI represents the gold standard for tracking corporate sustainability performance of the world's largest companies.
"We welcome the USA's Food & Drug Administration (FDA) shining a spotlight on the important issue of preventing youth access to vapour products and consumer safety. "We have always been clear that children should not use vapour products and we have had stringent measures in place to address this issue for some time. Accordingly, we share the FDA's concern that the marketing of some flavours could resonate with children.
BAT says it will cut about 2,300 roles in its 55,000-employee workforce globally with a focus on 'simplification and removal of management layers.'
British American Tobacco stock climbed on Thursday as the company announced plans to cut 2,300 jobs in a bid to shift towards cigarette alternatives.
BAT, which produces Dunhill and Lucky Strike, has been lumbering in its efforts to develop vaping and other e-cigarette products. How does British Airways compare with rivals on pilot pay? Big Tobacco’s new products still face regulatory challenges.
British American Tobacco is to axe 2,300 jobs, including a fifth of senior roles, as the cigarette maker restructures its business amid waves of industry change. The maker of Lucky Strike and Camel cigarettes on Thursday described the decision as an “important step” meant to “simplify its business and create a more efficient, agile and focused BAT”. The shake-up comes five months after Jack Bowles took the reins as chief executive and is part of his attempt to make the group more nimble and to focus on newer products with the traditional cigarette market in decline.
Shares of the second-largest tobacco company by sales were up 1.6 %, the biggest boost to the broader FTSE index on Thursday, after the maker of Lucky Strike and Dunhill cigarettes said it will cut 2,300 roles as it eliminates duplication and consolidates business units. The move by BAT, which employed more than 56,000 people at the end of last year, 629 of them senior managers, comes a day after President Donald Trump said that the U.S. would remove all flavored e-cigarettes from shelves, as officials warned millions of children had been drawn into nicotine addiction.
Jack Bowles’ plans for a “fit culture” stirs memories of heroic British footballers stubbing out cigarettes as they wheezed on to the pitch. Mr Bowles is chief executive of British American Tobacco, which simultaneously wishes to reduce its dependency on nicotine and middle managers. Big tobacco is coming late to the fashion for cutting layers of management. The MSCI World Tobacco Industry Index is down 40 per cent since July 2017.
WASHINGTON/LOS ANGELES, Sept 11 (Reuters) - The Trump administration announced plans on Wednesday to remove all flavored e-cigarettes from store shelves in a widening crackdown on vaping, as officials warned that sweet flavors had drawn millions of children into nicotine addiction. President Donald Trump and top U.S. officials expressed concern about surging teenage use of e-cigarettes, and the move comes as health officials are investigating a handful of deaths and potentially hundreds of lung illnesses tied to vaping. Health and Human Services Secretary Alex Azar said that, with Trump's blessing, the U.S. Food and Drug Administration was working on a "guidance document" that would lead to a ban of all e-cigarette flavors aside from tobacco flavoring.
A sixth person died from lung disease related to vaping but the U.S. Centers for Disease Control and Prevention is still trying to determine what is making more than 450 people nationwide ill.
U.S. health investigators are casting a wide net to understand what is sickening hundreds of vapers across the country and still have not ruled out any product on the market, even as vaping industry officials highlight the potential role of illegal cannabis products. Dr Dana Meaney-Delman is leading the U.S. Centers for Disease Control and Prevention's investigation into the culprit behind at least five confirmed deaths and 450 reported cases of lung illness linked with use of the devices. The agency is recommending that people refrain from the use of any electronic cigarette or vaping device until there is more conclusive evidence of a cause, she said in an interview.
LONDON, Sept. 9, 2019 /PRNewswire/ -- On 7th September 2019, the USA's Food & Drug Administration issued a statement in response to recent reports of respiratory illnesses following the use of vaping products. This statement included a recommendation that consumers should "avoid buying vaping products of any kind on the street, and to refrain from using THC oil or modifying/adding any substances to products purchased in stores". Below is British American Tobacco response to this statement.
Contrary to conventional wisdom, you don't need a hefty trust fund or deep pockets like mutual funds and other institutional players to start investing.
(Bloomberg Opinion) -- Something must be done. That’s often the response to a big deal like the planned $200 billion union between cigarette makers Philip Morris International Inc. and Altria Group Inc. For the duo’s competitors overseas, the temptation will be to indulge in some copycat dealmaking. In reality, bulking up would be a bad way to address their strategic challenges.There is some commercial logic in the tie-up of the two U.S. tobacco giants given their complementary businesses: each have sought to expand into alternative tobacco products in different ways. Altria took a minority stake in vaping group JUUL Labs Inc., while Philip Morris developed its IQOS system for heating rather than burning tobacco. Altria is focused solely on the U.S., Philip Morris on the rest of the world.Cost savings may be limited, but integration should be simple. Together, the pair can cross-sell some of their products in each other’s markets. By definition, there is no antitrust hurdle. It is harder to make comparable arguments for any combination involving British American Tobacco Plc, Japan Tobacco Inc. and Imperial Brands Plc.For BAT, which has a market value of 65 billion pounds ($79 billion), the appeal of a takeover of domestic rival Imperial, capitalized at 20 billion pounds, would merely be opportunistic and financial. Imperial’s shares have a dividend yield of more than 10%, a sign investors expect the annual payout will decline. The company’s net debt is forecast to fall to below three times Ebitda this year, whereas BAT’s net borrowings are expected to touch 3.6 times the same measure of profit. An all-share deal would therefore slightly improve BAT’s leverage and generate some cost savings from cutting duplicate functions.But such a transaction wouldn’t transform BAT’s position in tobacco alternatives. A slightly stronger financial position would be a modest benefit set beside the distraction of the integration and the likely need to make disposals to assuage antitrust concerns.Japan Tobacco, worth $42 billion, is substantially less geared, so an all-paper deal would achieve more in terms of reducing indebtedness. But it, too, could present antitrust issues for BAT. The presence of the Japanese government as lead shareholder would also be a complicating factor. It’s true both Imperial and Japan Tobacco are developing less risky tobacco products. But so, too, is BAT.One idea is that Japan Tobacco and BAT carve up Imperial’s geographical empire between them. The main outcome would, however, be to expand in conventional cigarettes. The wildcard buyer is Beijing-based China National Tobacco Corp.The only compelling M&A transaction would be one that enabled these companies to redeploy large parts of their manufacturing, marketing and distribution assets into products that weren’t just less harmful, but actually harmless. No banker has come up with that yet.The combination of Philip Morris and Altria may nudge others elsewhere toward M&A at some point. For now, the market’s caution around the mooted U.S. tie-up suggests the effect is going to be marginal. Don’t hold your breath for more deals.To contact the author of this story: Chris Hughes at firstname.lastname@example.orgTo contact the editor responsible for this story: Edward Evans at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Chris Hughes is a Bloomberg Opinion columnist covering deals. He previously worked for Reuters Breakingviews, as well as the Financial Times and the Independent newspaper.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.